The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

ABUS FINANCIAL STATEMENTS

Arbutus Biopharma Corp — balance sheet, income statement and cash flow trends

ABUSArbutus Biopharma Corp

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-100 M0100 M200 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue181.7 M $Gross Profit181.7 M $ · 100%Operating Income147.2 M $ · 81%Pre-tax Income153.1 M $ · 84%Net Income to Owners153.1 M $ · 84%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue181.7 M $+1,078.8%
Gross Profit181.7 M $—
Operating Income147.2 M $—
EBITDA153.2 M $—
Net Income to Owners153.1 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0100 M200 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets274 M
  • Equity258.7 M $94%
  • Current Liabilities3.4 M $1%
  • Long-term Liabilities11.9 M $4%

Key Figures

YoY change
Total Assets274 M $+165.4%
Total Liabilities15.3 M $-24.6%
Total Equity258.7 M $+211.8%
Cash & ST Investments92.6 M $-5.6%
Total Debt514 K $-89.7%
Net Debt-18.7 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-50 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-30 M-20 M-10 M0-24.6 M $Operating-10.8 M $Investing17.3 M $Financing-18.2 M $Net Change

Key Figures

YoY change
Operating Cash Flow-24.6 M $—
Capital Expenditures8.1 M $+9,285.4%
Free Cash Flow-24.6 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ABUS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.